StratDeck

Two stocks in Healthcare

Genus vs Haleon: profit, growth, debt and price compared

Haleon is stronger on 4 of 7 figures: sales growth, price for its expected profit, dividend and price trend. Genus is stronger on 2: profit margin and debt.

Figures as of 18 November 2026Yahoo Finance

Save both stocks to your watchlist and revisit their latest fundamentals.

Genus and Haleon side by side
GenusGNS.LHaleonHLN.L
Net marginStronger: 43.4%14.6%
Revenue growth, past year−4.10%Stronger: +2.20%
Debt to equityStronger: 14.0%50.2%
Forward P/E18.5×Stronger: 15.4×
Dividend yield1.56%Stronger: 2.13%
AnalystsBuy · 13Buy · 18
From its 200-day average−7.1%Stronger: −3.3%

Share price over the past year

  • Genus−14.3%
  • Haleon−7.1%

20 Nov 202518 Nov 2026

Genus or Haleon: which is stronger?

  • GNS.L

    Which is more profitable?

    Genus keeps more of each sale as profit: 43.4% against 14.6%.

  • HLN.L

    Which is growing its sales faster?

    Haleon is growing its sales faster: +2.20% over the past year, against −4.10%.

  • GNS.L

    Which has borrowed less?

    Genus has borrowed less: its debt is 14.0% of what its shareholders own, against 50.2% for Haleon.

  • HLN.L

    Which costs less for the profit it is expected to make?

    Haleon costs less for the profit it is expected to make: 15.4× its forward earnings, against 18.5×.

  • HLN.L

    Which pays more in dividends?

    Haleon pays more back in dividends for what a share costs: 2.13% a year, against 1.56%.

  • Which do analysts rate higher?

    Analysts rate both the same: Buy.

  • HLN.L

    Which is in the stronger price trend?

    Haleon's price is in the stronger trend: 3.3% below its 200-day average, against 7.1% below.

What each company does

GNS.LGenus

Genus plc produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia.

Reports results on 25 February 2027

HLN.LHaleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.

Reports results on 25 February 2027

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every UK healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.